Press releases

January 12, 2026

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Read more

January 07, 2026

Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference

Read more

December 30, 2025

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Read more

December 29, 2025

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Read more

December 19, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 24, 2025

Ultragenyx to Participate in Investor Conferences in December

Read more

November 21, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 04, 2025

Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update

Read more

November 04, 2025

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Read more

October 30, 2025

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups

Read more